OMMAX advised Schwabe on the acquisition of Synaptikon to expand its offering for digital brain health

We would like to congratulate Schwabe Group, a global group of pharmaceutical and healthcare businesses focusing on plant-based pharmaceuticals and health products, on the acquisition of a majority stake in Synaptikon GmbH, developer of the leading digital health application (DiGA) “NeuroNation” for patients with mild cognitive impairment.

OMMAX supported the Schwabe Group by conducting comprehensive commercial, tech, and people due diligence on Synaptikon:

• In-depth commercial assessment of Synaptikon’s NeuroNation apps (DiGA and B2C), including go-to-market, market dynamics, competitive landscape, customer analysis, and business plan assessment
• Holistic evaluation of Synaptikon’s organization, including the organizational set-up, capabilities, and culture
• Assessment of Synaptikon’s Tech, Data, and AI organization, including platform scalability, data foundations, and AI roadmap

Synaptikon GmbH is the digital healthcare company behind NeuroNation, the leading scientifically backed mobile app for personalized brain training with more than 32 million downloads globally. Founded in 2011, the platform combines cognitive assessment, adaptive therapy, and gamified exercises to support cognitive fitness and deliver measurable, real-world benefits for individuals with mild cognitive impairment. Available via app stores both as a free consumer app and as a certified DiGA reimbursed by health insurance providers, NeuroNation makes evidence-based cognitive training accessible at scale.

Schwabe Group’s acquisition will expand its portfolio focused on brain health toward the digital world to enable helping more patients and improve their lives across channels. NeuroNation complements Schwabe Group’s Tebonin® (EGb 761®) product, a leading Ginkgo-based brand for improvement of age-associated cognitive impairment and quality of life in mild dementia.

Dr. Isabel Freund, Senior Manager Global Business Development, commented:

“I would like to thank the OMMAX team for supporting our transaction from a very early stage until closing and beyond. The in-depth analyses and collaborative work during the commercial, people, and tech due diligence enabled us to make informed investment decisions with confidence, and we look forward to further collaboration in the future.”

Isabella Calderon Hoyos, Partner Strategy & Transactions at OMMAX, highlighted:

"Advising Schwabe Group on their acquisition by combining commercial, people, and tech insights to further strengthen their digital footprint was a privilege. We are proud of the comprehensive assessment that enabled our client to get an in-depth understanding of NeuroNation’s business and growth dynamics. We look forward to continuing our trustful and close collaboration in the future!"

Do you want to know more about OMMAX’s experience in transaction advisory? Get in touch with the author of this article. 

About Synaptikon GmbH

Synaptikon GmbH is a digital healthcare company specializing in personalized brain training through its mobile platform NeuroNation. Founded in 2011 and built on scientific research, the app, available for free or reimbursed by health insurance providers, combines cognitive profiling, adaptive therapy, and gamified learning to promote cognitive fitness and deliver measurable, real-life benefits for patients dealing with mild cognitive impairment.

For more information, please visit https://www.neuronation.com/

About Schwabe Group

The Schwabe Group is a leading international healthcare company specializing in herbal medicines and natural healthcare solutions. With a history spanning more than 160 years, the family-owned Group combines scientific research, pharmaceutical expertise, and a patient-centric approach to develop and market evidence-based therapies across a broad range of therapeutic areas. Operating globally through its pharmaceutical and healthcare subsidiaries, the Schwabe Group is committed to advancing innovation in phytomedicine and improving patients’ quality of life through sustainable and scientifically validated healthcare products.

For more information, please visit https://www.schwabe-group.com/de

About OMMAX – Building Digital Leaders 

OMMAX is a pan-European digital strategy consultancy shaping technology-, data-, and AI-powered businesses. Partnering with investors, corporates, and mid-sized companies, OMMAX delivers measurable impact through digital strategy and transformation across technology, data, and AI. Since 2011, OMMAX has delivered 3,000+ digital value creation projects, establishing itself as a trusted partner to private equity firms, global enterprises, and digital innovators.